In February, Idun Pharmaceuticals became the fourth company acquired by Pfizer in the last 15 months. While those transactions reflect different mixes of product and technology breadth, they suggest a greater alignment between the interests of some private biotechs, their investors, and potential pharma company acquirers, as well as an evolution in the deal calculus for choosing M&A over an alliance or IPO.
With an IPO currently a tough option for all but a smattering of
biotechs and their VCs, at least a few privately held companies
have been able to take another road. Their marching order could
well be: "If we can't go public, go Pfizer."
In February, Idun Pharmaceuticals Inc. became the fourth company Pfizer Inc. has acquired in the last 15 months...